US Edition
Published • loading... • Updated
ILiAD Biotechnologies of Weston raises $115M to advance whooping cough vaccine
Summary by Refresh Miami
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
ILiAD Biotechnologies of Weston raises $115M to advance whooping cough vaccine
ILiAD Biotechnologies, an advanced clinical stage biotechnology company based in Weston, announced it has raised an oversubscribed Series B round of $115 million. The company is focused on the prevention and treatment of diseases such as whooping cough. Pertussis, or whooping cough, is a life-threatening disease caused by the highly contagious respiratory bacterium Bordetella pertussis. According to U.S. Centers for Disease Control and Preventio…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
